Vectus Biosystems Ltd (ASX: VBS) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Vectus Biosystems Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $9.33 million
P/E Ratio 5.87
Dividend Yield 0.00%
Shares Outstanding 62.18 million
Earnings per share -0.026
Dividend per share N/A
Year To Date Return -8.33%
Earnings Yield 17.03%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Vectus Biosystems Ltd (ASX: VBS)
    Latest News

    Group of scientists cheering in the lab after the company received good news.
    Healthcare Shares

    Why is this ASX biotech share leaping 14% today?

    Human trial success is boosting this ASX biotech share today.

    Read more »

    VBS ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Vectus Biosystems Ltd

    Vectus Biosystems Ltd. operates as a drug discovery and development company. It researches a treatment for fibrosis and high blood pressure, which includes the therapeutics for diseases in the fibrotic market namely heart, kidney, and liver disease. Its lead compounds include VB0004, VB4-A32, VB4-A79, and VB4-P5. The company was founded by Karen Duggan on December 12, 2005 and is headquartered in Rosebery, Australia.

    VBS Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    09 Sep 2026 $0.16 $-0.01 -6.06% 13,300 $0.16 $0.16 $0.16
    07 Sep 2026 $0.17 $-0.02 -10.81% 15,118 $0.19 $0.19 $0.17
    02 Sep 2026 $0.19 $0.00 0.00% 8,150 $0.19 $0.19 $0.19
    31 Aug 2026 $0.19 $0.00 0.00% 2,252 $0.19 $0.19 $0.19
    28 Aug 2026 $0.19 $0.01 5.88% 22,050 $0.19 $0.19 $0.19
    27 Aug 2026 $0.17 $0.02 13.33% 14,939 $0.17 $0.17 $0.17
    26 Aug 2026 $0.15 $0.00 0.00% 13,190 $0.15 $0.15 $0.15
    25 Aug 2026 $0.15 $0.00 0.00% 4,859 $0.15 $0.15 $0.15
    24 Aug 2026 $0.15 $-0.01 -6.25% 3,050 $0.15 $0.15 $0.15
    21 Aug 2026 $0.16 $-0.01 -5.88% 61 $0.16 $0.16 $0.16
    20 Aug 2026 $0.17 $0.00 0.00% 35 $0.17 $0.17 $0.17
    19 Aug 2026 $0.17 $0.00 0.00% 11,764 $0.17 $0.17 $0.17
    18 Aug 2026 $0.17 $0.00 0.00% 30,018 $0.17 $0.17 $0.17
    17 Aug 2026 $0.17 $0.01 6.25% 31,968 $0.16 $0.17 $0.16

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    02 Sep 2026 Maurie Stang Exercise 316,000 $58,460
    Exercise of options.
    02 Sep 2026 Maurie Stang Issued 316,000 $58,460
    Exercise of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Maurie Stang Non-Executive Deputy ChairmanNon-Executive Director Dec 2005
    Mr Stang has four decades of experience building and managing companies in the healthcare and biotechnology industry in Australia and internationally. His business development and marketing skills have resulted in the commercialization of intellectual property across global markets. He has been the Executive Chairman of unlisted company Lumitron Technologies since 2016. He is also a member of Corporate Governance Committee.
    Dr Ronald Cecil Shnier Non-Executive DirectorNon-Executive Chairman Sep 2015
    Dr Shnier was a consultant specialist at RPAH between 1990 and 1993. He started one of Australia's first Private MRI practices in 1991 before becoming General Manager of Mayne's Diagnostic Imaging in 2007 and was its National Director for many years. He has served on several international MRI advisory boards. He has an involvement in clinical research and has lectured both in Australia and overseas. He is currently the Chief Medical Officer of I-MED Radiology network and an executive director on the board. He is also currently a non-executive director on the Board of Lumitron Technologies. He is the chairman of Disclosure Committee and member of Risk Management Committee.
    Ms Linda Ann Walters Non-Executive Director Dec 2024
    Ms Walters has operational, commercial and technical background across several life sciences, biotechnologies and health care companies. She has held senior leadership positions supporting both listed and unlisted Australian companies for over 25 years. She has made contribution to Vectus since its inception and public listing, and has a detailed knowledge of the Company's technologies, intellectual property (IP) and commercialization program. She is also a member of Corporate Governance Committee.
    Dr Tara Speranza Chief Executive OfficerChief Technology Officer May 2026
    -
    Mr Robert John Waring Company Secretary
    -
    Tara Speranza Chief Executive OfficerChief Technology Officer
    -
    Robert John Waring Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Kefford Holdings Pty Ltd <The Kefford Family A/C> 5,187,623 9.73%
    Ajjika Technology Pty Limited <The Ajjika A/C> 3,200,000 6.00%
    Bernard Stang 2,764,500 5.18%
    J P Morgan Nominees Australia Pty Limited 2,705,329 5.07%
    Energy Trading Systems Pty Ltd <The MPF A/C> 2,562,500 4.80%
    Maurie Stang 2,285,952 4.29%
    Towns Corporation Pty Ltd <Pae Family A/C> 1,984,976 3.72%
    Gleneagle Securities Nominees Pty Limited 1,611,596 3.02%
    Bennelong Resources Pty Ltd <John Egan Super Fund A/C> 1,500,000 2.81%
    Spinite Pty Ltd 1,435,773 2.69%
    Citicorp Nominees Pty Limited 1,168,124 2.19%
    Grizzly Holdings Pty Limited 999,680 1.87%
    Gleneagle Securities (Aust) Pty Ltd 938,675 1.76%
    Exit Out Pty Ltd <The Discretionary A/C> 900,000 1.69%
    Buttonwood Nominees Pty Ltd 859,112 1.61%
    Robert Richter + Anne Lyell Richter <Robert Richter S/F No2 A/C> 825,291 1.55%
    Esklaw Pty Ltd <Tom Forrester Family A/C> 814,000 1.53%
    T S Rai 2 Pty Ltd <Websta Super Fund A/C> 800,000 1.50%
    Paul Alexander Ehrlich + Lauren Stacey Ehrlich <PAE & LSE Super Fund A/C> 730,000 1.37%
    TDF Properties Pty Ltd <The TDF Property A/C> 599,339 1.13%

    Profile

    since

    Note